NRG-GY012: Randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer.
Bobbie J RimelDanielle EnserroDavid P BenderCamille Gunderson JacksonAnnie TanNitya AlluriMark BorowskyJohn MoroneyAndrea Wahner HendricksonFloor J BackesElizabeth SwisherMatthew PowellHelen J MackayPublished in: Cancer (2023)
The combination of cediranib and olaparib demonstrated modest clinical efficacy; however, the primary end point of the study was not met. The combination was safe without unexpected toxicity.